• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症免疫疗法的恰当时机、恰当组合、恰当顺序和恰当传递。

The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy.

机构信息

Korea University Anam Hospital, Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Seoul, Republic of Korea.

Korea University Anam Hospital, Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Seoul, Republic of Korea.

出版信息

J Control Release. 2021 Mar 10;331:321-334. doi: 10.1016/j.jconrel.2021.01.009. Epub 2021 Jan 9.

DOI:10.1016/j.jconrel.2021.01.009
PMID:33434599
Abstract

Cancer immunotherapy (CI) represented by immune checkpoint inhibitors (ICIs) presents a new paradigm for cancer treatment. However, the types of cancer that attain a therapeutic benefit from ICIs are limited, and the efficacy of these treatments does not meet expectations. To date, research on ICIs has mainly focused on identifying biomarkers and patient characteristics that can enhance the therapeutic effect on tumors. However, studies on combinational strategies for CI are being actively conducted to overcome the resistance to ICI treatment. Moreover, it has been confirmed that dramatic anticancer effects are achieved through "neoadjuvant" immunotherapy with ICIs in treatment-naïve cancer patients; consequently, it has become necessary to consider how to best apply cancer immunotherapies for patients, even with respect to their tumor stages. In this review, we sought to discuss the right timing of ICI treatment in consideration of the progression of cancer with a changing tumor-immune microenvironment. Furthermore, we investigated which types of combinational treatments and their corresponding sequences of administration could optimize the therapeutic effect of ICIs to expand the applicable target of ICIs and increase their therapeutic efficacy. Finally, we discussed several delivery pathways and methods that can maximize the effect of ICIs.

摘要

癌症免疫疗法(CI)以免疫检查点抑制剂(ICI)为代表,为癌症治疗带来了新的范例。然而,能从 ICI 中获得治疗益处的癌症类型有限,这些治疗的疗效也不尽如人意。迄今为止,ICI 的研究主要集中在确定能够增强对肿瘤治疗效果的生物标志物和患者特征上。然而,正在积极开展针对 CI 的联合策略研究,以克服对 ICI 治疗的耐药性。此外,已经证实,在未经治疗的癌症患者中进行“新辅助”ICI 免疫治疗可以实现显著的抗癌效果;因此,有必要考虑如何为患者最佳应用癌症免疫疗法,即使考虑到他们的肿瘤分期。在这篇综述中,我们试图讨论在考虑肿瘤免疫微环境不断变化的情况下,ICI 治疗的最佳时机。此外,我们研究了哪种类型的联合治疗及其相应的给药顺序可以优化 ICI 的治疗效果,以扩大 ICI 的适用靶点并提高其治疗效果。最后,我们讨论了几种可以最大限度发挥 ICI 效果的给药途径和方法。

相似文献

1
The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy.癌症免疫疗法的恰当时机、恰当组合、恰当顺序和恰当传递。
J Control Release. 2021 Mar 10;331:321-334. doi: 10.1016/j.jconrel.2021.01.009. Epub 2021 Jan 9.
2
Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.与癌症中免疫逃逸和免疫检查点抑制剂耐药相关的致癌信号通路。
Semin Cancer Biol. 2020 Oct;65:51-64. doi: 10.1016/j.semcancer.2019.11.011. Epub 2019 Dec 23.
3
Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.免疫检查点抑制剂联合治疗:当前的努力和成功的重要方面。
Drug Resist Updat. 2019 Jul;45:13-29. doi: 10.1016/j.drup.2019.07.004. Epub 2019 Jul 29.
4
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition.当前肿瘤内免疫治疗策略——超越免疫检查点抑制。
Eur J Cancer. 2021 Nov;157:493-510. doi: 10.1016/j.ejca.2021.08.004. Epub 2021 Sep 21.
5
Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.影响肿瘤应答者的因素和接受免疫检查点抑制剂治疗的癌症患者毒性的预测生物标志物。
Int Immunopharmacol. 2020 Aug;85:106628. doi: 10.1016/j.intimp.2020.106628. Epub 2020 May 28.
6
Acquired Resistance to Immune Checkpoint Inhibitors.获得性免疫检查点抑制剂耐药。
Cancer Cell. 2020 Apr 13;37(4):443-455. doi: 10.1016/j.ccell.2020.03.017.
7
Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.靶向髓系来源抑制细胞,克服免疫检查点抑制剂耐药的一种有前景的策略。
Front Immunol. 2020 May 15;11:783. doi: 10.3389/fimmu.2020.00783. eCollection 2020.
8
Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.不同组织学类型的肿瘤浸润淋巴细胞在检查点抑制下的常见表型动力学:对临床结局的影响。
Cytotherapy. 2020 Apr;22(4):204-213. doi: 10.1016/j.jcyt.2020.01.010. Epub 2020 Mar 20.
9
T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).基于 T 细胞的血液系统恶性肿瘤免疫治疗,A 部分:免疫检查点抑制剂(ICI)和双特异性 T 细胞衔接器(BiTE)的 SWOT 分析。
Anticancer Res. 2021 Mar;41(3):1123-1141. doi: 10.21873/anticanres.14870.
10
Managing side effects of immune checkpoint inhibitors in breast cancer.乳腺癌中免疫检查点抑制剂副作用的管理
Crit Rev Oncol Hematol. 2021 Jun;162:103354. doi: 10.1016/j.critrevonc.2021.103354. Epub 2021 May 21.

引用本文的文献

1
Magnetic hyperthermia-based therapies for cancer targeting: current progress and future perspectives.基于磁热疗的癌症靶向治疗:当前进展与未来展望。
Med Oncol. 2025 Aug 28;42(10):453. doi: 10.1007/s12032-025-03020-9.
2
A Comprehensive Review of Thermosensitive Hydrogels: Mechanism, Optimization Strategies, and Applications.热敏水凝胶的全面综述:作用机制、优化策略及应用
Gels. 2025 Jul 14;11(7):544. doi: 10.3390/gels11070544.
3
Nanomaterials for Combating Cancer while Safeguarding Organs: Safe and Effective Integrative Tumor Therapy.
用于抗癌同时保护器官的纳米材料:安全有效的综合肿瘤治疗
Biomater Res. 2025 Jun 12;29:0165. doi: 10.34133/bmr.0165. eCollection 2025.
4
Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies.颠覆鼻咽癌治疗模式:干细胞和基因修饰细胞治疗的影响、挑战与策略。
Front Immunol. 2024 Oct 10;15:1484535. doi: 10.3389/fimmu.2024.1484535. eCollection 2024.
5
Metabolic modulation of melanoma enhances the therapeutic potential of immune checkpoint inhibitors.黑色素瘤的代谢调节增强了免疫检查点抑制剂的治疗潜力。
Front Oncol. 2024 Oct 1;14:1428802. doi: 10.3389/fonc.2024.1428802. eCollection 2024.
6
Synergistic Enhancement of Chemotherapy-Induced Cell Death and Antitumor Efficacy against Tumoral T-Cell Lymphoblasts by IMMUNEPOTENT CRP.免疫活性 C 反应蛋白增强化疗诱导的肿瘤 T 淋巴细胞白血病细胞死亡和抗肿瘤疗效的协同作用。
Int J Mol Sci. 2024 Jul 20;25(14):7938. doi: 10.3390/ijms25147938.
7
Novel insights into paclitaxel's role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment.紫杉醇在增强乳腺癌治疗中 PD-1 阻断作用方面对肿瘤相关巨噬细胞作用的新见解。
J Immunother Cancer. 2024 Jul 15;12(7):e008864. doi: 10.1136/jitc-2024-008864.
8
Fundamentals and Applications of Focused Ultrasound-Assisted Cancer Immune Checkpoint Inhibition for Solid Tumors.聚焦超声辅助癌症免疫检查点抑制治疗实体瘤的基础与应用
Pharmaceutics. 2024 Mar 16;16(3):411. doi: 10.3390/pharmaceutics16030411.
9
Biomaterial-based 3D modeling of glioblastoma multiforme.基于生物材料的多形性胶质母细胞瘤3D建模。
Cancer Pathog Ther. 2023 Jan 9;1(3):177-194. doi: 10.1016/j.cpt.2023.01.002. eCollection 2023 Jul.
10
Effects of "Timing It Right" nursing on clinical outcome and psychological resilience for lung cancer patients undergoing radical thoracoscopic surgery.“把握时机”护理对行根治性胸腔镜手术的肺癌患者临床结局及心理复原力的影响
Am J Transl Res. 2024 Jan 15;16(1):179-189. doi: 10.62347/LUMW7355. eCollection 2024.